Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Aug
31
Today In Oncology
How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting
Subspecialization in Oncology Is Increasing—But Unevenly Distributed Across the Country
Identifying CNS Tumors With Multianalyte Cerebrospinal Fluid Test
Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy
Real-World Incidence and Management of Infusion-Related Reactions to Monoclonal Antibody Therapy
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo